Notice of Intent to Sole Source Illumina Reagents

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Illumina, Inc. for reagents. The procedures in use in the lab were validated by Illumina branded reagenty under the Clinical Laboratory Improvement Act (CLIA) guidelines. Even where available, to change to a third party supplier would require an extensive re-validation of >75% of the sequencing procedures in use across the branch. We would be unable to report results for the length of time of such re-validation. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within six (6) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to William Brannen at [email protected] by July 6, 2022 at 2:00 P.M.